OSR Holdings Inc (OSRH) - Total Liabilities
Based on the latest financial reports, OSR Holdings Inc (OSRH) has total liabilities worth $44.20 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is OSR Holdings Inc growing its equity to track the company's year-over-year net asset growth rate.
OSR Holdings Inc - Total Liabilities Trend (2020–2025)
This chart illustrates how OSR Holdings Inc's total liabilities have evolved over time, based on quarterly financial data. See OSRH cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
OSR Holdings Inc Competitors by Total Liabilities
The table below lists competitors of OSR Holdings Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
PeterLabs Holdings Bhd
KLSE:0171
|
Malaysia | RM21.70 Million |
|
Diamyd Medical AB (publ)
ST:DMYD-B
|
Sweden | Skr83.83 Million |
|
Zelan Bhd
KLSE:2283
|
Malaysia | RM524.27 Million |
|
iRobot Corporation
NASDAQ:IRBT
|
USA | $508.46 Million |
|
Biovica International AB (publ)
ST:BIOVIC-B
|
Sweden | Skr31.14 Million |
|
IntegraFin Holdings plc
LSE:IHP
|
UK | GBX33.85 Billion |
|
Yuyu Pharma Inc
KO:000225
|
Korea | ₩64.72 Billion |
|
Office Properties Income Trust
NASDAQ:OPI
|
USA | $2.50 Billion |
Liability Composition Analysis (2020–2025)
This chart breaks down OSR Holdings Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see OSR Holdings Inc market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.57 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how OSR Holdings Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for OSR Holdings Inc (2020–2025)
The table below shows the annual total liabilities of OSR Holdings Inc from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $44.20 Million | +402.92% |
| 2024-12-31 | $8.79 Million | +113.93% |
| 2023-12-31 | $4.11 Million | +23763.66% |
| 2022-12-31 | $17.22K | -97.57% |
| 2021-12-31 | $707.21K | +119.93% |
| 2020-12-31 | $321.56K | -- |
About OSR Holdings Inc
OSR Holdings, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Germany, Switzerland, and South Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma completed phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the… Read more